Drug Trial Radar · NCT06898060
To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
Last checked: Nov 19, 2026Latest source record: Mar 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
282
Planned (sponsor's estimate)
Start
Jun 2025
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of QLG2128 in the treatment of postmenopausal women with osteoporosis and at high risk of fracture.
Conditions
- Postmenopausal Women With Osteoporosis
Interventions
QLG2128Drug
Recommended dosage is 80 μg subcutaneously once daily,52week
Teriparatide InjectionDrug
Recommended dosage is 20μg subcutaneously once daily,52week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in Bone Mineral Density (BMD) of Lumbar Spine From Baseline to 52 WeekTime frame: Baseline to 52 Week
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.